Catherine Squarcioni-Prost

Bobigny, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

Journal: JAMA dermatology

Published: March 05, 2025

Autoimmune bullous dermatosis in children: French guidelines.

Autoimmune bullous dermatosis in children: French guidelines.

Journal: Annales de dermatologie et de venereologie

Published: November 05, 2024

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

Journal: JAMA dermatology

Published: January 24, 2024

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review.

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review.

Journal: Frontiers in immunology

Published: June 20, 2023

Bullous presentation of demodicosis in a young immunocompetent patient.

Bullous presentation of demodicosis in a young immunocompetent patient.

Journal: International journal of dermatology

Published: May 23, 2023

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.

Journal: The British journal of dermatology

Published: May 17, 2023

Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.

Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.

Journal: Frontiers in immunology

Published: April 07, 2022

Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Journal: Frontiers in immunology

Published: February 11, 2022

Bronchial involvement in mucous membrane pemphigoid: 2 cases and a literature review.

Bronchial involvement in mucous membrane pemphigoid: 2 cases and a literature review.

Journal: Annales de dermatologie et de venereologie

Published: January 10, 2022

Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

Journal: Acta dermato-venereologica

Published: March 09, 2021

International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.

International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.

Journal: The British journal of dermatology

Published: October 15, 2020

Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores.

Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores.

Journal: The British journal of dermatology

Published: May 07, 2020

Showing 1-12 of 37

Last Updated: 09/26/2026